Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study

Ann Allergy Asthma Immunol. 2015 Jun;114(6):499-503. doi: 10.1016/j.anai.2015.04.005. Epub 2015 Apr 29.

Abstract

Background: Acute attacks of hereditary angioedema are characterized by recurrent localized edema. These attacks can be life threatening and are associated with substantial morbidity and mortality.

Objective: To determine factors associated with hospital admission of patients with an acute attack of hereditary angioedema presenting at the emergency department.

Methods: This was a multicenter prospective observational study of consecutive patients (January 2011 through December 2013) experiencing an acute hereditary angioedema attack and presenting at the emergency department at 1 of 4 French reference centers for bradykinin-mediated angioedema. Attacks requiring hospital admission were compared with those not requiring admission.

Results: Of 57 attacks in 29 patients, 17 (30%) led to hospital admission. In multivariate analysis, laryngeal and facial involvements were associated with hospital admission (odds ratio 18.6, 95% confidence interval 3.9-88; odds ratio 7.7, 95% confidence interval 1.4-43.4, respectively). Self-injection of icatibant at home was associated with non-admission (odds ratio 0.06, 95% confidence interval 0.01-0.61). The course was favorable in all 57 cases. No upper airway management was required.

Conclusion: Most patients attended the emergency department because they were running out of medication and did not know that emergency treatment could be self-administered. Risk factors associated with hospital admission were laryngeal and facial involvement, whereas self-injection of icatibant was associated with a return home.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Adult
  • Angioedemas, Hereditary / drug therapy*
  • Angioedemas, Hereditary / pathology
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Bradykinin / analogs & derivatives*
  • Bradykinin / therapeutic use
  • Bradykinin B2 Receptor Antagonists / therapeutic use
  • Complement C1 Inhibitor Protein / genetics
  • Emergency Service, Hospital / statistics & numerical data*
  • Female
  • France
  • Humans
  • Male
  • Patient Admission / statistics & numerical data*
  • Prospective Studies

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Bradykinin B2 Receptor Antagonists
  • Complement C1 Inhibitor Protein
  • icatibant
  • Bradykinin